The Department of Veterans Affairs has opened enrollment in a randomized, placebo-controlled trial testing whether semaglutide, the GLP-1 medication sold as Ozempic and Wegovy, can reduce drinking in veterans with alcohol use disorder. Recruitment began on July 28, and the VA announced the study two days later.
The design is the news. Nearly everything the public has heard about GLP-1 drugs and alcohol has come from observational data, health-record analyses and patient anecdotes, none of which can establish whether the medication itself is responsible for reduced drinking. This trial randomizes participants and gives half of them a placebo.
Semaglutide is approved by the FDA to treat type 2 diabetes and for chronic weight management. It is not approved for alcohol use disorder, and the VA said explicitly that veterans should not self-medicate or substitute a GLP-1 for established addiction treatment.
Inside the Trial Design
The study is formally the Cessation or Reduction of Alcohol Consumption in Veterans trial, shortened to CRAVE. According to the VA announcement of the trial, it will enroll more than 600 veterans ages 18 to 80 with moderate or severe alcohol use disorder at 18 VA medical centers nationwide, from Palo Alto and Seattle to Houston, Philadelphia and Durham.
Participants will be randomly assigned to receive weekly injections of either semaglutide or a matching placebo, followed by a safety evaluation. Researchers will measure changes in alcohol consumption, overall health, and quality of life.
The trial registration on ClinicalTrials.gov lists the study as a Phase 3, double-blind, placebo-controlled trial, with drinking measured through the Timeline Follow-Back, a validated calendar-based interview that reconstructs daily alcohol intake. The registry entry describes a 28-week treatment period followed by a four-week safety assessment, with dosing that starts low and titrates upward to a maximum of 2.4 milligrams weekly. The VA's public announcement describes a 24-week injection period. Readers should treat the registry as the operative protocol document while that difference is clarified.
Neither figure changes the central point. Enrollment across 18 sites takes many months, and results are years away.
The Agency Chose a Trial Over Existing Data
VA Secretary Doug Collins said the department is uniquely situated to launch this kind of research. "By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery," he said in a statement carried by Military Times.
The VA cited an analysis published in March that found patients receiving GLP-1 medications had lower rates of alcohol use disorder and other substance use disorders than similar patients taking other diabetes drugs. That analysis drew on electronic health records from more than 600,000 VA patients with diabetes. Ziyad Al-Aly, the study's lead author and a chief researcher at the VA St. Louis Health Care System, told the Associated Press that the drugs appear to act on a shared mechanism, saying they work against the root cause of these different addictions.
That earlier work was observational. It compared people who were already taking these medications for other reasons, which means differences in who gets prescribed a GLP-1 could explain part of the association. A prior small Phase 2 trial of 48 adults found that weekly semaglutide reduced drinking and craving over nine weeks, but the sample was too small to settle the question.
Launching a randomized trial of this size is a direct acknowledgment that the existing evidence base is not strong enough to change prescribing.
The Scale of the Problem Behind the Study
More than 400,000 veterans nationwide have been diagnosed with alcohol use disorder, according to the department, which also notes that some estimates put the prevalence among U.S. adults near 11 percent.
The treatment gap is the reason a new medication class draws this much attention. Only three medications are FDA-approved for alcohol use disorder, and the overwhelming majority of Americans who meet criteria for the condition receive none of them. Naltrexone, the most widely prescribed option, works for some patients and not others, and uptake has remained low for decades.
Whether semaglutide belongs in that toolkit is precisely what has not been established.
Practical Takeaways for Veterans and Families
The most important practical point is what this announcement does not mean. It does not mean a veteran should ask a clinician to prescribe semaglutide for drinking, and it does not mean anyone should buy compounded or online semaglutide for that purpose. The VA specifically discouraged self-medicating or replacing proven treatments with GLP-1 medications or any other unprescribed substance.
Veterans with moderate or severe alcohol use disorder who are interested in participating can contact their local VA medical center or search for the trial on ClinicalTrials.gov, as the department directed. Enrolling in a placebo-controlled trial means accepting a roughly even chance of receiving no active drug for the duration, which is a real consideration for anyone whose drinking is causing immediate harm.
For families, the useful framing is that evidence-based treatment already exists and is available at VA facilities today. Medications, structured counseling and combined approaches have decades of trial support behind them. A veteran who needs help this month should not wait for a study that will take years to report.
Anyone in crisis can reach the Veterans Crisis Line by dialing 988 and pressing 1.
Milestones Worth Watching
Other GLP-1 and addiction trials are already underway across academic and government research programs, and some of those results are expected to arrive over the next few years. Several may report before CRAVE does.
Tolerability is its own open question. GLP-1 medications commonly cause gastrointestinal side effects, and how well a population with moderate to severe alcohol use disorder tolerates weekly injections over six months is one of the things the trial's built-in safety assessment is designed to capture. MedicalDaily will report the results when they are published.
Frequently Asked Questions
What is the CRAVE trial? It is a randomized, double-blind, placebo-controlled VA trial testing whether weekly semaglutide injections reduce drinking in veterans with moderate or severe alcohol use disorder. Enrollment opened July 28, 2026.
How many people are involved and where? More than 600 veterans ages 18 to 80 at 18 VA medical centers nationwide, according to the VA announcement.
Is semaglutide approved to treat alcohol use disorder? No. It is approved for type 2 diabetes and chronic weight management only. The VA has explicitly discouraged using it for drinking outside a clinical trial.
Why does a randomized trial matter more than the earlier research? Most prior evidence came from observational analyses of people already prescribed these drugs, which cannot separate the medication's effect from differences among patients. Randomization and a placebo arm can.
How can a veteran join? Contact your local VA medical center or search for the trial on ClinicalTrials.gov, as directed by the department. Participants have roughly an even chance of receiving a placebo.
When will results be available? Not soon. The trial is still recruiting, the treatment period runs about half a year per participant, and enrollment across 18 sites takes many months before analysis can begin.
What treatment is available for alcohol use disorder right now? Three FDA-approved medications and structured behavioral treatment are available through VA facilities and civilian care. Veterans in crisis can dial 988 and press 1.
